Skip to main content

Levothyroxine Sodium

FDA recalls

25 rows

DateCompany and reasonClass
Sep 28, 2026Pfizer
Subpotent Drug: confirmed out-of-specification (OOS) assay during stability testing.
Class II · Ongoing
Aug 5, 2026Accord Healthcare, Inc.
Subpotent Drug
Class II · Ongoing
Jul 12, 2026Major Pharmaceuticals
Subpotent Drug
Class II · Ongoing
Jun 7, 2026Accord Healthcare, Inc.
Subpotent Drug
Class II · Ongoing
Feb 25, 2026Macleods Pharma USA, Inc
Subpotent Drug
Class II · Ongoing
Sep 15, 2025Accord Healthcare, Inc.
Subpotent: During long term stability testing of Levothyroxine Sodium Tablets USP for 88 mcg, the assay content was observed below the approved specification range.
Class II · Ongoing
Jul 28, 2025Pfizer
Subpotent drug
Class II · Ongoing
Jun 19, 2025Accord Healthcare, Inc.
Subpotent Drug: Assay below the approved specification
Class II · Ongoing
May 28, 2025Macleods Pharmaceuticals Ltd
Presence of a foreign substance: black hair found embedded in tablet.
Class III · Ongoing
Apr 9, 2025Accord Healthcare, Inc.
Subpotent
Class II · Ongoing
Mar 6, 2025Mylan Institutional, Inc.
Super-Potent Drug: Out of specification potency results were obtained.
Class II · Ongoing
Dec 19, 2024Lupin Pharmaceuticals Inc.
Failed Impurities/Degradation Specifications: Out of specifications result observed in the drug substance for impurity test during 3-month long term stability study.
Class II · Terminated
Nov 18, 2024Mylan Institutional, Inc.
Subpotent and Superpotent Drug
Class II · Ongoing
Nov 7, 2024Accord Healthcare, Inc.
Subpotent drug
Class II · Terminated
Oct 16, 2023AbbVie Inc.
Labeling: Wrong Barcode- One of every forty unit dose blister will contain incorrect barcode information that causes a 125mcg unit dose is scanned as 200mcg unit dose.
Class III · Ongoing
Jan 29, 2023Ibsa Pharma Inc
Subpotent Drug
Class II · Terminated
Mar 14, 2021Cardinal Health Inc.
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Class II · Terminated
Dec 5, 2018Pfizer Inc.
Superpotent Drug.
Class II · Terminated
Nov 6, 2016Pfizer Inc.
Superpotent
Class II · Terminated
Apr 29, 2013King Legacy, A Wholly Owned Subsidiary of Pfizer
Subpotent Drug: The products were below specification for potency at the expiry stability point.
Class II · Terminated
Mar 27, 2013Pfizer Inc.
Chemical contamination: emission of strong odor after package was opened
Class II · Completed
Mar 27, 2013Pfizer Inc.
Chemical contamination: emission of strong odor after package was opened..
Class II · Completed
Mar 27, 2013Pfizer Inc.
Chemical contamination: emission of strong odor after package was opened.
Class II · Completed
Dec 3, 2012Abbott Laboratories
Labeling: Error on Declared Strength. Product labeled to contain 150 mcg tablets actually contained 75 mcg tablets.
Class II · Terminated
Jul 18, 2012Abbott Laboratories
Defective Container: A number of Synthroid bottles have a localized thin wall defect on the bottom which may potentially impact the stability of the tablets.
Class II · Terminated

← Back to Levothyroxine Sodium

Sources: CMS Medicare Part D Prescribers 2024; CMS Open Payments 2025 (general payments; a payment is not evidence of wrongdoing); FDA enforcement reports (openFDA).